Clinical Trial

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Study acronym: ISG-MCS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-03-11; most recent amendment 2026-03-24.
Status change: Active, Not Recruiting → Recruiting 2023-09-12
Status change: Not Yet Recruiting → Active, Not Recruiting 2021-10-29
Trial Details
NCT Number NCT04305548
Lead Sponsor Italian Sarcoma Group
Collaborators: PharmaMar
Conditions Mesenchymal Chondrosarcoma
Enrollment 16 participants
Start Date 2021-09-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27